Last reviewed · How we verify
Rd
Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.
Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins. Used for Hematologic malignancies (specific indications pending confirmation).
At a glance
| Generic name | Rd |
|---|---|
| Also known as | Lenalidomide +Dexamethasone |
| Sponsor | Ascentage Pharma Group Inc. |
| Drug class | BCL-2 inhibitor |
| Target | BCL-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Rd (likely referring to a BCL-2 inhibitor in development by Ascentage Pharma) works by inhibiting anti-apoptotic BCL-2 family proteins, allowing pro-apoptotic signals to proceed and trigger programmed cell death in malignant cells. This mechanism is particularly relevant in hematologic malignancies where BCL-2 overexpression drives survival of cancer cells.
Approved indications
- Hematologic malignancies (specific indications pending confirmation)
Common side effects
- Tumor lysis syndrome
- Neutropenia
- Thrombocytopenia
- Gastrointestinal toxicity
Key clinical trials
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (PHASE1)
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (PHASE3)
- Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (PHASE2)
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease (PHASE2)
- Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations (NA)
- A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma (PHASE1, PHASE2)
- A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rd CI brief — competitive landscape report
- Rd updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI